ORPHA:2596
Myopathy and diabetes mellitus
Publications
107
46.7th percentile
Trials
0
Interventional, condition-specific
Researchers
641
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic, DNA-related disorder characterized by slowly muscular weakness (proximal greater than distal), predominantly involving the facial muscles and scapular girdle, associated with insulin-dependent diabetes mellitus. Neurological involvement and may be variably observed.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010773
- MeSH:C564026
- OMIM:500002
- UMLS:C1839028
Additional Mondo synonyms (3)
mitochondrial myopathy with diabetes · mitochondrial myopathy, lipid type · myopathy and diabetes mellitus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
107 matched papers (46 in last 10 years) Source
- Phenotype characterisedPresent
54 HPO annotations (e.g. Proximal amyotrophy; Babinski sign; Exercise intolerance) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
54
Associated phenotypes · MONDO:0010773
- Proximal amyotrophy
- Babinski sign
- Exercise intolerance
- Difficulty running
- Respiratory distress
Showing 5 of 54 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
107
107 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
107 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
46 in the last 10 years · high confidence · 46.7th percentile (publications denominator)
Phrase hits: 107 · MeSH hits: 0
Who's working on it?
641
Distinct author names in 107 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Chinnery PF6 papers · 2023
Department of Neurology, University of Newcastle upon Tyne, UK.
Papers in Europe PMC - 02DiMauro S4 papers · 2010Papers in Europe PMC
- 03Hanna MG4 papers · 1999
Department of Clinical Neurology, Institute of Neurology, London, UK. mhanna@ion.ucl.ac.uk
Papers in Europe PMC - 04Bonilla E3 papers · 2008Papers in Europe PMC
- 05Turnbull DM3 papers · 2012Papers in Europe PMC
- 06Bennett MJ2 papers · 1999Papers in Europe PMC
- 07Brooke MH2 papers · 1986Papers in Europe PMC
- 08Carroll JE2 papers · 1986Papers in Europe PMC
- 09Cicero AFG2 papers · 2021
Italian Nutraceutical Society (SINut), Via Guelfa 9, 40138 Bologna, Italy.
Papers in Europe PMC - 10Colletti A2 papers · 2021
Department of Science and Drug Technology, University of Turin, 10125 Turin, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 16 · after dedupe 16 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 16 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (16)
- ctis·2025-522361-30-00·Authorised, recruiting·A Phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G variant.
skipped — LLM skipped (--skip-llm)
- ctis·2024-515129-27-00·Authorised·Assess efficacy of intra-arterial autologous myogenic stam cell therapy for m.3243A>G mutation carriers
skipped — LLM skipped (--skip-llm)
- ctis·2024-510763-35-00·Authorised, ongoing·An Off-Label Single Arm Clinical Study to Evaluate the Efficacy and Safety of doxecitine and doxribtimine in Adult Subjects with Thymidine Kinase 2 (TK2) Deficiency
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86135778·No longer recruiting·Comparative analysis of adult-onset Still's disease (AOSD) treatments
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14442671·No longer recruiting·A study to evaluate the drug-drug interaction potential of pralsetinib in combination with substrates of various transporters or CYP enzymes or a combined oral contraceptive in participants with advanced or metastatic solid tumors that are not responsive to standard therapies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN39960384·Recruiting·Long-term follow-up of participants with electronic health records from the HPS2-THRIVE study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10176118·No longer recruiting·A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valproate in paediatric and adult patients with Wolfram Syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15073006·No longer recruiting·Lowering Events in Non-proliferative retinopathy in Scotland
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN27159806·No longer recruiting·A clinical study to test the safety and the efficacy of a single-pill combination of 2 antihypertensive and 1 lipid-lowering drug in patients already well treated with the concomitant administration of the same three drugs on separate tablets
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17787139·Stopped·Randomised trial of pravastatin versus placebo for the prevention of high blood pressure in pregnancy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN21164124·No longer recruiting·Effect of coenzyme Q10 in fibromyalgia patients: study of symptoms and gene expression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN48678192·No longer recruiting·Randomized evaluation of the effects of anacetrapib through lipid-modification
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN54010405·No longer recruiting·The safety and efficacy of CCX140-B in subjects with type 2 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30019040·No longer recruiting·HCQ-01 Trial: evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic human immunodeficiency virus (HIV) infected patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN91866393·No longer recruiting·Multicentre, randomised, triple-blind, placebo-controlled study to evaluate the clinical efficacy and safety of an oral rehydration solution (Recuperat-ion®) in the treatment of fibromyalgia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN64894118·No longer recruiting·A 12-week, randomised, double-blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Myopathy and diabetes mellitus — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Myopathy and diabetes mellitus" OR "mitochondrial myopathy with diabetes" OR "mitochondrial myopathy, lipid type"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Myopathy and diabetes mellitus" OR "mitochondrial myopathy with diabetes" OR "mitochondrial myopathy, lipid type"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T20:38:43.192Z
